{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:52:26Z","timestamp":1795042346123,"version":"4.10.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["TT-ZAPBOF 33049"],"award-info":[{"award-number":["TT-ZAPBOF 33049"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    African trypanosomiasis is a disease caused by\n                    <jats:italic>Trypanosoma brucei<\/jats:italic>\n                    parasites with limited treatment options.\n                    <jats:italic>Trypanosoma<\/jats:italic>\n                    is unable to synthesize purines de novo and relies solely on their uptake and interconversion from the host, constituting purine nucleoside analogues a potential source of antitrypanosomal agents. Here we combine structural elements from known trypanocidal nucleoside analogues to develop a series of 3\u2019-deoxy-7-deazaadenosine nucleosides, and investigate their effects against African trypanosomes. 3\u2019-Deoxytubercidin is a highly potent trypanocide in vitro and displays curative activity in animal models of acute and CNS-stage disease, even at low doses and oral administration. Whole-genome RNAi screening reveals that the\u00a0P2 nucleoside transporter and adenosine kinase are involved in the uptake and activation, respectively, of this analogue. This is confirmed by P1 and P2\u00a0transporter assays and nucleotide pool analysis. 3\u2019-Deoxytubercidin is a promising lead to treat late-stage sleeping sickness.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-13522-6","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T08:43:21Z","timestamp":1576226601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-3484","authenticated-orcid":false,"given":"Fabian","family":"Hulpia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3530-0567","authenticated-orcid":false,"given":"Dorien","family":"Mabille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo D.","family":"Campagnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-6513","authenticated-orcid":false,"given":"Isabel","family":"Roditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-1827","authenticated-orcid":false,"given":"Harry P.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-3202","authenticated-orcid":false,"given":"Guy","family":"Caljon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-1264","authenticated-orcid":false,"given":"Serge","family":"Van Calenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"13522_CR1","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","volume":"390","author":"P B\u00fcscher","year":"2017","unstructured":"B\u00fcscher, P., Cecchi, G., Jamonneau, V. & Priotto, G. Human African trypanosomiasis. Lancet 390, 2397\u20132409 (2017).","journal-title":"Lancet"},{"key":"13522_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","volume":"15","author":"MC Field","year":"2017","unstructured":"Field, M. C. et al. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat. Rev. Microbiol. 15, 217\u2013231 (2017).","journal-title":"Nat. Rev. Microbiol."},{"key":"13522_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","volume":"12","author":"PGE Kennedy","year":"2013","unstructured":"Kennedy, P. G. E. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet Neurol. 12, 186\u2013194 (2013).","journal-title":"Lancet Neurol."},{"key":"13522_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2217\/fmb.11.44","volume":"6","author":"R Brun","year":"2011","unstructured":"Brun, R., Don, R., Jacobs, R. T., Wang, M. Z. & Barrett, M. P. Development of novel drugs for human African trypanosomiasis. Fut. Microbiol. 6, 677\u2013691 (2011).","journal-title":"Fut. Microbiol."},{"key":"13522_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","volume":"107","author":"P Babokhov","year":"2013","unstructured":"Babokhov, P., Sanyaolu, A. O., Oyibo, W. A., Fagbenro-Beyioku, A. F. & Iriemenam, N. C. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog. Glob. Health 107, 242\u2013252 (2013).","journal-title":"Pathog. Glob. Health"},{"key":"13522_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","volume":"391","author":"V Mesu","year":"2018","unstructured":"Mesu, V. et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 391, 144\u2013154 (2018).","journal-title":"Lancet"},{"key":"13522_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/0035-9203(94)90430-8","volume":"88","author":"J P\u00e9pin","year":"1994","unstructured":"P\u00e9pin, J. et al. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Trans. R. Soc. Trop. Med. Hyg. 88, 447\u2013452 (1994).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"13522_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ana.21429","volume":"64","author":"PG Kennedy","year":"2008","unstructured":"Kennedy, P. G. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann. Neurol. 64, 116\u2013126 (2008).","journal-title":"Ann. Neurol."},{"key":"13522_CR9","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1128\/AAC.00332-10","volume":"54","author":"AY Sokolova","year":"2010","unstructured":"Sokolova, A. Y. et al. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob. Agents Chemother. 54, 2893\u20132900 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13522_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jac\/dkv376","volume":"71","author":"S Wyllie","year":"2016","unstructured":"Wyllie, S. et al. Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei. J. Antimicrob. Chemother. 71, 625\u2013634 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"13522_CR11","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1128\/AAC.01787-09","volume":"54","author":"M Berg","year":"2010","unstructured":"Berg, M. et al. Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis. Antimicrob. Agents Chemother. 54, 1900\u20131908 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13522_CR12","doi-asserted-by":"publisher","first-page":"13147","DOI":"10.1021\/bi990829u","volume":"38","author":"RW Miles","year":"1999","unstructured":"Miles, R. W. et al. Iminoribitol transition state analogue inhibitors of protozoan nucleoside hydrolases. Biochemistry 38, 13147\u201313154 (1999).","journal-title":"Biochemistry"},{"key":"13522_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0960-894X(00)00608-9","volume":"11","author":"KJ Kennedy","year":"2001","unstructured":"Kennedy, K. J., Bressi, J. C. & Gelb, M. H. A disubstituted NAD+ analogue is a nanomolar inhibitor of trypanosomal glyceraldehyde-3-phosphate dehydrogenase. Bioorg. Med. Chem. Lett. 11, 95\u201398 (2001).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"13522_CR14","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.2174\/092986710791556023","volume":"17","author":"M Berg","year":"2010","unstructured":"Berg, M., der Veken, Van., Goeminne, P., Haemers, A. & Augustyns, A. K. Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy? Curr. Med. Chem. 17, 2456\u20132481 (2010).","journal-title":"Curr. Med. Chem."},{"key":"13522_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/0035-9203(66)90146-5","volume":"60","author":"J Williamson","year":"1966","unstructured":"Williamson, J. Cordycepin, an antitumour antibiotic with trypanocidal properties. Trans. R. Soc. Trop. Med. Hyg. 60, 8\u20138 (1966).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"13522_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep08771","volume":"5","author":"I Pena","year":"2015","unstructured":"Pena, I. et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci. Rep. 5, 8771 (2015).","journal-title":"Sci. Rep."},{"key":"13522_CR17","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1371\/journal.pntd.0000495","volume":"3","author":"SK Vodnala","year":"2009","unstructured":"Vodnala, S. K. et al. Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS Negl. Trop. Dis. 3, e495 (2009).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"13522_CR18","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1021\/jm401530a","volume":"56","author":"SK Vodnala","year":"2013","unstructured":"Vodnala, S. K. et al. Structure\u2013activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis. J. Med. Chem. 56, 9861\u20139873 (2013).","journal-title":"J. Med. Chem."},{"key":"13522_CR19","first-page":"422","volume":"63","author":"J Williamson","year":"1969","unstructured":"Williamson, J. Activity of drugs on Trypanosoma congolense in vitro at 37 degrees C. Trans. R. Soc. Trop. Med. Hyg. 63, 422\u2013423 (1969).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"13522_CR20","doi-asserted-by":"publisher","first-page":"e0004972","DOI":"10.1371\/journal.pntd.0004972","volume":"10","author":"JI Aoki","year":"2016","unstructured":"Aoki, J. I. et al. Characterization of a novel endoplasmic reticulum protein involved in tubercidin resistance in Leishmania major. PLoS Negl. Trop. Dis. 10, e0004972 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"13522_CR21","doi-asserted-by":"publisher","first-page":"e02719","DOI":"10.1128\/AAC.02719-16","volume":"61","author":"F Ranjbarian","year":"2017","unstructured":"Ranjbarian, F. et al. 9-(2\u2032-Deoxy-2\u2032-fluoro-\u03b2-d-arabinofuranosyl) adenine is a potent antitrypanosomal adenosine analogue that circumvents transport-related drug resistance. Antimicrob. Agents Chemother. 61, e02719 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13522_CR22","doi-asserted-by":"crossref","unstructured":"Ho, H. T. B. & Wang, J. in Drug Transporters: Molecular Characterization and Role in Drug Disposition 2nd edn, 107\u2013126 (Wiley, 2014).","DOI":"10.1002\/9781118705308.ch7"},{"key":"13522_CR23","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1086\/496896","volume":"192","author":"ME Rottenberg","year":"2005","unstructured":"Rottenberg, M. E. et al. Treatment of African trypanosomiasis with cordycepin and adenosine deaminase inhibitors in a mouse model. J. Infect. Dis. 192, 1658\u20131665 (2005).","journal-title":"J. Infect. Dis."},{"key":"13522_CR24","doi-asserted-by":"publisher","first-page":"46596","DOI":"10.1074\/jbc.M309320200","volume":"278","author":"ME Drew","year":"2003","unstructured":"Drew, M. E. et al. The adenosine analog tubercidin inhibits glycolysis in Trypanosoma brucei as revealed by an RNA interference library. J. Biol. Chem. 278, 46596\u201346600 (2003).","journal-title":"J. Biol. Chem."},{"key":"13522_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ejmech.2018.12.050","volume":"164","author":"F Hulpia","year":"2019","unstructured":"Hulpia, F. et al. Revisiting tubercidin against kinetoplastid parasites: aromatic substitutions at position 7 improve activity and reduce toxicity. Eur. J. Med. Chem. 164, 689\u2013705 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"13522_CR26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1124\/mol.106.031351","volume":"71","author":"DJ Bridges","year":"2007","unstructured":"Bridges, D. J. et al. Loss of the high-affinity pentamidine transporter Is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Mol. Pharmacol. 71, 1098\u20131108 (2007).","journal-title":"Mol. Pharmacol."},{"key":"13522_CR27","doi-asserted-by":"publisher","first-page":"e0004791","DOI":"10.1371\/journal.pntd.0004791","volume":"10","author":"AA Eze","year":"2016","unstructured":"Eze, A. A. et al. Reduced mitochondrial membrane potential is a late adaptation of Trypanosoma brucei brucei to isometamidium preceded by mutations in the \u03b3-subunit of the F1Fo-ATPase. PLoS Negl. Trop. Dis. 10, e0004791 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"13522_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jmoldx.2014.02.006","volume":"16","author":"P Gonzalez-Andrade","year":"2014","unstructured":"Gonzalez-Andrade, P. et al. Diagnosis of trypanosomatid infections: targeting the spliced leader RNA. J. Mol. Diagn. 16, 400\u2013404 (2014).","journal-title":"J. Mol. Diagn."},{"key":"13522_CR29","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1124\/mol.56.6.1162","volume":"56","author":"HP de Koning","year":"1999","unstructured":"de Koning, H. P. & Jarvis, S. M. Adenosine transporters in bloodstream forms of Trypanosoma brucei brucei: substrate recognition motifs and affinity for trypanocidal drugs. Mol. Pharmacol. 56, 1162\u20131170 (1999).","journal-title":"Mol. Pharmacol."},{"key":"13522_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/361173a0","volume":"361","author":"NS Carter","year":"1993","unstructured":"Carter, N. S. & Fairlamb, A. H. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361, 173\u2013176 (1993).","journal-title":"Nature"},{"key":"13522_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/mmi.12979","volume":"96","author":"JC Munday","year":"2015","unstructured":"Munday, J. C. et al. Functional analysis of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1) and the proposal of a structural model for the protein. Mol. Microbiol. 96, 887\u2013900 (2015).","journal-title":"Mol. Microbiol."},{"key":"13522_CR32","doi-asserted-by":"publisher","first-page":"34028","DOI":"10.1074\/jbc.M109.049726","volume":"284","author":"CJ Collar","year":"2009","unstructured":"Collar, C. J. et al. Predictive computational models of substrate binding by a nucleoside transporter. J. Biol. Chem. 284, 34028\u201334035 (2009).","journal-title":"J. Biol. Chem."},{"key":"13522_CR33","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1074\/jbc.M705603200","volume":"283","author":"M Vodnala","year":"2008","unstructured":"Vodnala, M. et al. Adenosine kinase mediates high affinity adenosine salvage in Trypanosoma brucei. J. Biol. Chem. 283, 5380\u20135388 (2008).","journal-title":"J. Biol. Chem."},{"key":"13522_CR34","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","volume":"116","author":"J Shelton","year":"2016","unstructured":"Shelton, J. et al. Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs. Chem. Rev. 116, 14379\u201314455 (2016).","journal-title":"Chem. Rev."},{"key":"13522_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695\u2013747 (2016).","journal-title":"Clin. Microbiol. Rev."},{"key":"13522_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.vetpar.2016.07.011","volume":"227","author":"RM Reguera","year":"2016","unstructured":"Reguera, R. M., Moran, M., Perez-Pertejo, Y., Garcia-Estrada, C. & Balana-Fouce, R. Current status on prevention and treatment of canine leishmaniasis. Vet. Parasitol. 227, 98\u2013114 (2016).","journal-title":"Vet. Parasitol."},{"key":"13522_CR37","doi-asserted-by":"publisher","first-page":"14256","DOI":"10.1074\/jbc.M112.447441","volume":"288","author":"I Cestari","year":"2013","unstructured":"Cestari, I. & Stuart, K. Inhibition of isoleucyl-tRNA synthetase as a potential treatment for human African trypanosomiasis. J. Biol. Chem. 288, 14256\u201314263 (2013).","journal-title":"J. Biol. Chem."},{"key":"13522_CR38","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1139\/v73-198","volume":"51","author":"MJ Robins","year":"1973","unstructured":"Robins, M. J., McCarthy, Jr,J. R., Jones, R. A. & Mengel, R. Nucleic acid related compounds. 5. The transformation of formycin and tubercidin into 2\u2032- and 3\u2032-deoxynucleosides. Can. J. Chem. 51, 1313\u20131321 (1973).","journal-title":"Can. J. Chem."},{"key":"13522_CR39","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1128\/AAC.48.10.3944-3953.2004","volume":"48","author":"DB Olsen","year":"2004","unstructured":"Olsen, D. B. et al. A 7-deaza-adenosine analog Is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48, 3944\u20133953 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13522_CR40","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1126\/science.1925539","volume":"252","author":"DK Wilson","year":"1991","unstructured":"Wilson, D. K., Rudolph, F. B. & Quiocho, F. A. Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science 252, 1278\u20131284 (1991).","journal-title":"Science"},{"key":"13522_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.femsre.2005.03.004","volume":"29","author":"HP de Koning","year":"2005","unstructured":"de Koning, H. P., Bridges, D. J. & Burchmore, R. J. S. Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. FEMS Microbiol. Rev. 29, 987\u20131020 (2005).","journal-title":"FEMS Microbiol. Rev."},{"key":"13522_CR42","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/mmi.13083","volume":"97","author":"Q Li","year":"2015","unstructured":"Li, Q. et al. GMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway. Mol. Microbiol. 97, 1006\u20131020 (2015).","journal-title":"Mol. Microbiol."},{"key":"13522_CR43","doi-asserted-by":"publisher","first-page":"21713","DOI":"10.1074\/jbc.271.36.21713","volume":"271","author":"DW Parkin","year":"1996","unstructured":"Parkin, D. W. Purine-specific nucleoside N-ribohydrolase from Trypanosoma brucei brucei: purification, specificity and kinetic mechanism. J. Biol. Chem. 271, 21713\u201321719 (1996).","journal-title":"J. Biol. Chem."},{"key":"13522_CR44","doi-asserted-by":"publisher","first-page":"11717","DOI":"10.1074\/jbc.M116.715615","volume":"291","author":"M Vodnala","year":"2016","unstructured":"Vodnala, M., Ranjbarian, F., Pavlova, A., de Koning, H. P. & Hofer, A. Trypanosoma brucei methylthioadenosine phosphorylase protects the parasite from the antitrypanosomal effect of deoxyadenosine: implications for the pharmacology of adenosine metabolites. J. Biol. Chem. 291, 11717\u201311726 (2016).","journal-title":"J. Biol. Chem."},{"key":"13522_CR45","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1128\/AAC.00458-07","volume":"51","author":"A Luscher","year":"2007","unstructured":"Luscher, A., Onal, P., Schweingruber, A. M. & Maser, P. Adenosine kinase of Trypanosoma brucei and its role in susceptibility to adenosine antimetabolites. Antimicrob. Agents Chemother. 51, 3895\u20133901 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13522_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0166-6851(97)00129-1","volume":"89","author":"HP de Koning","year":"1997","unstructured":"de Koning, H. P. & Jarvis, S. M. Purine nucleobase transport in bloodstream forms of Trypanosoma brucei brucei is mediated by two novel transporters. Mol. Biochem. Parasitol. 89, 245\u2013258 (1997).","journal-title":"Mol. Biochem. Parasitol."},{"key":"13522_CR47","doi-asserted-by":"publisher","first-page":"9486","DOI":"10.1074\/jbc.273.16.9486","volume":"273","author":"HP de Koning","year":"1998","unstructured":"de Koning, H. P., Watson, C. J. & Jarvis, S. M. Characterization of a nucleoside\/proton symporter in procyclic Trypanosoma brucei brucei. J. Biol. Chem. 273, 9486\u20139494 (1998).","journal-title":"J. Biol. Chem."},{"key":"13522_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1128\/EC.2.5.1003-1008.2003","volume":"2","author":"E Matovu","year":"2003","unstructured":"Matovu, E. et al. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot. Cell 2, 1003\u20131008 (2003).","journal-title":"Eukaryot. Cell"},{"key":"13522_CR49","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1177\/1087057115569155","volume":"20","author":"M Kaiser","year":"2015","unstructured":"Kaiser, M., Maes, L., Tadoori, L. P., Spangenberg, T. & Ioset, J. R. Repurposing of the open access malaria box for kinetoplastid diseases identifies novel active scaffolds against trypanosomatids. J. Biomol. Screen. 20, 634\u2013645 (2015).","journal-title":"J. Biomol. Screen."},{"key":"13522_CR50","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1128\/AAC.42.11.2858","volume":"42","author":"R Kaminsky","year":"1998","unstructured":"Kaminsky, R. & Brun, R. In vitro and in vivo activities of trybizine hydrochloride against various pathogenic trypanosome species. Antimicrob. Agents Chemother. 42, 2858\u20132862 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13522_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0166-6851(99)00002-X","volume":"99","author":"E Wirtz","year":"1999","unstructured":"Wirtz, E., Leal, S., Ochatt, C. & Cross, G. M. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol. Biochem. Parasitol. 99, 89\u2013101 (1999).","journal-title":"Mol. Biochem. Parasitol."},{"key":"13522_CR52","doi-asserted-by":"publisher","first-page":"e3054","DOI":"10.1371\/journal.pntd.0003054","volume":"8","author":"N Van Reet","year":"2014","unstructured":"Van Reet, N., Van de Vyver, H., Pyana, P. P., Van der Linden, A. M. & B\u00fcscher, P. A Panel of Trypanosoma brucei strains tagged with blue and red-shifted luciferases for bioluminescent imaging in murine infection models. PLoS Negl. Trop. Dis. 8, e3054 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"13522_CR53","doi-asserted-by":"publisher","first-page":"e0156289","DOI":"10.1371\/journal.pone.0156289","volume":"11","author":"N Eissa","year":"2016","unstructured":"Eissa, N. et al. Stability of reference genes for messenger RNA quantification by real-time PCR in mouse dextran sodium sulfate experimental colitis. PLoS ONE 11, e0156289 (2016).","journal-title":"PLoS ONE"},{"key":"13522_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.molbiopara.2010.09.002","volume":"175","author":"G Schumann Burkard","year":"2011","unstructured":"Schumann Burkard, G., Jutzi, P. & Roditi, I. Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. Mol. Biochem. Parasitol. 175, 91\u201394 (2011).","journal-title":"Mol. Biochem. Parasitol."},{"key":"13522_CR55","doi-asserted-by":"publisher","first-page":"26149","DOI":"10.1074\/jbc.M202835200","volume":"277","author":"LJM Wallace","year":"2002","unstructured":"Wallace, L. J. M., Candlish, D. & De Koning, H. P. Different substrate recognition motifs of human and trypanosome nucleobase transporters: selective uptake of purine antimetabolites. J. Biol. Chem. 277, 26149\u201326156 (2002).","journal-title":"J. Biol. Chem."},{"key":"13522_CR56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.molbiopara.2010.03.007","volume":"172","author":"M Brenndorfer","year":"2010","unstructured":"Brenndorfer, M. & Boshart, M. Selection of reference genes for mRNA quantification in Trypanosoma brucei. Mol. Biochem. Parasitol. 172, 52\u201355 (2010).","journal-title":"Mol. Biochem. Parasitol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13522-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T21:23:43Z","timestamp":1671225823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13522"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13522-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5564"}}